Comparative survival outcomes of hyperthermic intraperitoneal chemotherapy, intraperitoneal chemotherapy and intravenous chemotherapy for primary advanced ovarian cancer: a network meta-analysis

HIGHLIGHTS

  • who: Qin Tang et al. from the Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China have published the research work: Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis, in the Journal: (JOURNAL) of 15/08/2022
  • what: The authors aimed to compare the outcomes and adverse events of hyperthermic (HIPEC) (IP)and intravenous (IP)for primary advanced ovarian cancer.
  • how: The analysis results showed that HIPEC2 (carboplatin with area under the curve 10 . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?